Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
American Society of Nephrology to hold virtual annual meeting » 08:06
10/19/20
10/19
08:06
10/19/20
08:06
AKBA

Akebia

$3.76 /

+0.11 (+3.01%)

, FOLD

Amicus

$17.20 /

+0.25 (+1.47%)

, FMS

Fresenius Medical

$41.93 /

+0.59 (+1.43%)

, DRNA

Dicerna

$20.44 /

-0.24 (-1.16%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$56.81 /

-0.93 (-1.61%)

, KDNY

Chinook Therapeutics

$16.55 /

+0.52 (+3.24%)

, RTRX

Retrophin

$21.93 /

+0.6 (+2.81%)

, OMER

Omeros

$11.48 /

+0.03 (+0.26%)

, OM

Outset Medical

$48.06 /

-1.87 (-3.75%)

, NVS

Novartis

$86.21 /

+0.79 (+0.92%)

, GSK

GlaxoSmithKline

$36.56 /

+0.585 (+1.63%)

, SNY

Sanofi

$50.31 /

+0.38 (+0.76%)

, ALNY

Alnylam

$145.40 /

+1.52 (+1.06%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$235.87 /

+0.88 (+0.37%)

, AZN

AstraZeneca

$53.02 /

+0.45 (+0.86%)

, BAX

Baxter

$81.79 /

+1.1 (+1.36%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$28.80 /

-0.63 (-2.14%)

, ICUI

ICU Medical

$199.25 /

-3.11 (-1.54%)

, TCDA

Tricida

$9.17 /

+0.13 (+1.44%)

, VRTX

Vertex Pharmaceuticals

$218.06 /

+2.99 (+1.39%)

Kidney Week 2020: Virtual…

Kidney Week 2020: Virtual Annual Meeting will be held on October 19-25. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$218.06 /

+2.99 (+1.39%)

TCDA Tricida
$9.17 /

+0.13 (+1.44%)

SNY Sanofi
$50.31 /

+0.38 (+0.76%)

RTRX Retrophin
$21.93 /

+0.6 (+2.81%)

OMER Omeros
$11.48 /

+0.03 (+0.26%)

NVS Novartis
$86.21 /

+0.79 (+0.92%)

KDNY Chinook Therapeutics
$16.55 /

+0.52 (+3.24%)

ICUI ICU Medical
$199.25 /

-3.11 (-1.54%)

GSK GlaxoSmithKline
$36.56 /

+0.585 (+1.63%)

FOLD Amicus
$17.20 /

+0.25 (+1.47%)

FMS Fresenius Medical
$41.93 /

+0.59 (+1.43%)

DRNA Dicerna
$20.44 /

-0.24 (-1.16%)

CCXI ChemoCentryx
$56.81 /

-0.93 (-1.61%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.79 /

+1.1 (+1.36%)

AZN AstraZeneca
$53.02 /

+0.45 (+0.86%)

AMGN Amgen
$235.87 /

+0.88 (+0.37%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALNY Alnylam
$145.40 /

+1.52 (+1.06%)

AKBA Akebia
$3.76 /

+0.11 (+3.01%)

AKBA Akebia
$3.76 /

+0.11 (+3.01%)

09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
09/04/20 BTIG
Akebia price target lowered to $6 from $26 at BTIG
09/04/20 Mizuho
Akebia price target lowered to $6 from $17 at Mizuho
FOLD Amicus
$17.20 /

+0.25 (+1.47%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$41.93 /

+0.59 (+1.43%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$20.44 /

-0.24 (-1.16%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$56.81 /

-0.93 (-1.61%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$16.55 /

+0.52 (+3.24%)

10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$21.93 /

+0.6 (+2.81%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$11.48 /

+0.03 (+0.26%)

09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
03/04/20 Wedbush
Omeros price target raised to $22 from $18 at Wedbush
03/03/20 Cantor Fitzgerald
Omeros shares can 'significantly rerate' from here, says Cantor Fitzgerald
OM Outset Medical
$48.06 /

-1.87 (-3.75%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$86.21 /

+0.79 (+0.92%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
GSK GlaxoSmithKline
$36.56 /

+0.585 (+1.63%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
SNY Sanofi
$50.31 /

+0.38 (+0.76%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
ALNY Alnylam
$145.40 /

+1.52 (+1.06%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$235.87 /

+0.88 (+0.37%)

10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$53.02 /

+0.45 (+0.86%)

10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
09/28/20 Maxim
Maxim upgrades Inovio to Buy, says shares oversold after vaccine 'speed bump'
BAX Baxter
$81.79 /

+1.1 (+1.36%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
10/02/20 Deutsche Bank
Bayer price target lowered to EUR 64 from EUR 82 at Deutsche Bank
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$28.80 /

-0.63 (-2.14%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$199.25 /

-3.11 (-1.54%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$9.17 /

+0.13 (+1.44%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
VRTX Vertex Pharmaceuticals
$218.06 /

+2.99 (+1.39%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
VRTX Vertex Pharmaceuticals
$218.06 /

+2.99 (+1.39%)

TCDA Tricida
$9.17 /

+0.13 (+1.44%)

SNY Sanofi
$50.31 /

+0.38 (+0.76%)

RTRX Retrophin
$21.93 /

+0.6 (+2.81%)

OMER Omeros
$11.48 /

+0.03 (+0.26%)

NVS Novartis
$86.21 /

+0.79 (+0.92%)

ICUI ICU Medical
$199.25 /

-3.11 (-1.54%)

GSK GlaxoSmithKline
$36.56 /

+0.585 (+1.63%)

FOLD Amicus
$17.20 /

+0.25 (+1.47%)

DRNA Dicerna
$20.44 /

-0.24 (-1.16%)

CCXI ChemoCentryx
$56.81 /

-0.93 (-1.61%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.79 /

+1.1 (+1.36%)

AZN AstraZeneca
$53.02 /

+0.45 (+0.86%)

AMGN Amgen
$235.87 /

+0.88 (+0.37%)

ALNY Alnylam
$145.40 /

+1.52 (+1.06%)

AKBA Akebia
$3.76 /

+0.11 (+3.01%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
SNY Sanofi
$50.31 /

+0.38 (+0.76%)

NVS Novartis
$86.21 /

+0.79 (+0.92%)

GSK GlaxoSmithKline
$36.56 /

+0.585 (+1.63%)

FOLD Amicus
$17.20 /

+0.25 (+1.47%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.02 /

+0.45 (+0.86%)

AMGN Amgen
$235.87 /

+0.88 (+0.37%)

AKBA Akebia
$3.76 /

+0.11 (+3.01%)

VRTX Vertex Pharmaceuticals
$218.06 /

+2.99 (+1.39%)

TCDA Tricida
$9.17 /

+0.13 (+1.44%)

SNY Sanofi
$50.31 /

+0.38 (+0.76%)

OMER Omeros
$11.48 /

+0.03 (+0.26%)

OM Outset Medical
$48.06 /

-1.87 (-3.75%)

NVS Novartis
$86.21 /

+0.79 (+0.92%)

GSK GlaxoSmithKline
$36.56 /

+0.585 (+1.63%)

CCXI ChemoCentryx
$56.81 /

-0.93 (-1.61%)

CALT Calliditas Therapeutics
$28.80 /

-0.63 (-2.14%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAX Baxter
$81.79 /

+1.1 (+1.36%)

AZN AstraZeneca
$53.02 /

+0.45 (+0.86%)

AMGN Amgen
$235.87 /

+0.88 (+0.37%)

ALNY Alnylam
$145.40 /

+1.52 (+1.06%)

AKBA Akebia
$3.76 /

+0.11 (+3.01%)

VRTX Vertex Pharmaceuticals
$218.06 /

+2.99 (+1.39%)

SNY Sanofi
$50.31 /

+0.38 (+0.76%)

KDNY Chinook Therapeutics
$16.55 /

+0.52 (+3.24%)

GSK GlaxoSmithKline
$36.56 /

+0.585 (+1.63%)

AZN AstraZeneca
$53.02 /

+0.45 (+0.86%)

AMGN Amgen
$235.87 /

+0.88 (+0.37%)

AKBA Akebia
$3.76 /

+0.11 (+3.01%)

Friday
Hot Stocks
Alnylam receives positive CHMP opinion for OXLUMO » 06:01
10/16/20
10/16
06:01
10/16/20
06:01
ALNY

Alnylam

$143.88 /

-0.24 (-0.17%)

Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of lumasiran, an investigational RNAi therapeutic targeting the hydroxyacid oxidase 1 mRNA - encoding glycolate oxidase - in development for the treatment of primary hyperoxaluria type 1. If approved by the European Commission, lumasiran will be marketed in Europe under the brand name OXLUMO. The FDA has granted a Priority Review for the NDA and has set an action date of December 3, under the Prescription Drug User Fee Act.

ShowHide Related Items >><<
ALNY Alnylam
$143.88 /

-0.24 (-0.17%)

ALNY Alnylam
$143.88 /

-0.24 (-0.17%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALNY Alnylam
$143.88 /

-0.24 (-0.17%)

ALNY Alnylam
$143.88 /

-0.24 (-0.17%)

Over a week ago
Hot Stocks
Retrophin to present abstracts at ASN Kidney Week 2020 » 16:02
10/09/20
10/09
16:02
10/09/20
16:02
RTRX

Retrophin

$20.67 /

+0.15 (+0.73%)

Retrophin announced that…

Retrophin announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology Kidney Week 2020 Reimagined. The company and its collaborators will also feature encore presentations of preclinical data supporting the potential for sparsentan to protect kidney function in additional rare glomerular diseases. ASN Kidney Week 2020 Reimagined is being held virtually October 19-25, 2020.

ShowHide Related Items >><<
RTRX Retrophin
$20.67 /

+0.15 (+0.73%)

RTRX Retrophin
$20.67 /

+0.15 (+0.73%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
RTRX Retrophin
$20.67 /

+0.15 (+0.73%)

  • 09
    Jun
Conference/Events
Wedbush biotech analyst to hold analyst/industry conference call » 09:25
10/08/20
10/08
09:25
10/08/20
09:25
RTRX

Retrophin

$20.63 /

+0.08 (+0.39%)

Biotechnology Analyst…

Biotechnology Analyst Chico, along with Dr. Howard Trachtman, Professor of Pediatrics Dept at NYU Grossman School of Medicine, discuss Focal Segmental Glomerulosclerosis (FSGS) Therapies in development and the impact to Retrophin (RTRX) on an Analyst/Industry conference call to be held on October 8 at 10 am.

ShowHide Related Items >><<
RTRX Retrophin
$20.63 /

+0.08 (+0.39%)

RTRX Retrophin
$20.63 /

+0.08 (+0.39%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
RTRX Retrophin
$20.63 /

+0.08 (+0.39%)

  • 09
    Jun
Conference/Events
Wedbush biotech analyst to hold analyst/industry conference call » 04:55
10/08/20
10/08
04:55
10/08/20
04:55
RTRX

Retrophin

$20.63 /

+0.08 (+0.39%)

Biotechnology Analyst…

Biotechnology Analyst Chico, along with Dr. Howard Trachtman, Professor of Pediatrics Dept at NYU Grossman School of Medicine, discuss Focal Segmental Glomerulosclerosis (FSGS) Therapies in development and the impact to Retrophin (RTRX) on an Analyst/Industry conference call to be held on October 8 at 10 am.

ShowHide Related Items >><<
RTRX Retrophin
$20.63 /

+0.08 (+0.39%)

RTRX Retrophin
$20.63 /

+0.08 (+0.39%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
RTRX Retrophin
$20.63 /

+0.08 (+0.39%)

  • 09
    Jun
Initiation
Chinook Therapeutics initiated with an Outperform at SVB Leerink » 08:34
10/07/20
10/07
08:34
10/07/20
08:34
KDNY

Chinook Therapeutics

$14.75 /

+0.16 (+1.10%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz initiated coverage of Chinook Therapeutics with an Outperform rating and $38 price target. Schwartz believes Chinook's dual-pronged approach to the IgA nephropathy market, through two differentiated assets, offers a unique value proposition for investors. The analyst believes Chinook is poised to become a formidable competitor in the kidney space.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$14.75 /

+0.16 (+1.10%)

KDNY Chinook Therapeutics
$14.75 /

+0.16 (+1.10%)

10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
KDNY Chinook Therapeutics
$14.75 /

+0.16 (+1.10%)

Initiation
Chinook Therapeutics initiated with an Outperform at SVB Leerink » 07:23
10/07/20
10/07
07:23
10/07/20
07:23
KDNY

Chinook Therapeutics

$14.75 /

+0.16 (+1.10%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz initiated coverage of Chinook Therapeutics with an Outperform rating and $38 price target.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$14.75 /

+0.16 (+1.10%)

KDNY Chinook Therapeutics
$14.75 /

+0.16 (+1.10%)

Options
Two new option listings and three option delistings on October 6th » 08:30
10/06/20
10/06
08:30
10/06/20
08:30
KDNY

Chinook Therapeutics

$14.59 /

+0.58 (+4.14%)

, PLTR

Palantir

$9.06 /

-0.13 (-1.41%)

, ADRO

Aduro Biotech

$0.00 /

+ (+0.00%)

, AMTD

TD Ameritrade

$40.00 /

-0.79 (-1.94%)

, NBL

Noble Energy

$8.44 /

+ (+0.00%)

New option listings for…

New option listings for October 6th include Chinook Therapeutics Inc (KDNY) and Palantir Technologies Inc (Class A Stock) (PLTR). Option delistings effective October 6th include Aduro Biotech Inc (ADRO), TD Ameritrade Holding Corporation (AMTD), and Noble Energy Inc (NBL).

ShowHide Related Items >><<
PLTR Palantir
$9.06 /

-0.13 (-1.41%)

NBL Noble Energy
$8.44 /

+ (+0.00%)

KDNY Chinook Therapeutics
$14.59 /

+0.58 (+4.14%)

AMTD TD Ameritrade
$40.00 /

-0.79 (-1.94%)

ADRO Aduro Biotech
$0.00 /

+ (+0.00%)

KDNY Chinook Therapeutics
$14.59 /

+0.58 (+4.14%)

PLTR Palantir
$9.06 /

-0.13 (-1.41%)

ADRO Aduro Biotech
$0.00 /

+ (+0.00%)

06/02/20 H.C. Wainwright
H.C. Wainwright trims Aduro price target to $3.75 after Chinook deal announced
01/10/20 Cowen
Aduro downgraded to Market Perform on limited visibility at Cowen
01/10/20 Cowen
Aduro Biotech downgraded to Market Perform from Outperform at Cowen
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
AMTD TD Ameritrade
$40.00 /

-0.79 (-1.94%)

07/24/20 Morgan Stanley
Morgan Stanley says Schwab share price doesn't reflect TD Ameritrade benefits
07/09/20 Wolfe Research
TD Ameritrade upgraded to Peer Perform from Underperform at Wolfe Research
06/08/20 Wolfe Research
TD Ameritrade downgraded to Underperform from Outperform at Wolfe Research
05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
NBL Noble Energy
$8.44 /

+ (+0.00%)

09/11/20 Morgan Stanley
Merits of Chevron deal remain despite activist uncertainty, says Morgan Stanley
08/31/20 Citi
Noble Energy downgraded to Neutral on Chevron deal at Citi
08/28/20 Citi
Noble Energy downgraded to Neutral from Buy at Citi
08/26/20 Piper Sandler
Piper Sandler upgrades Noble Midstream with 40% total return potential
PLTR Palantir
$9.06 /

-0.13 (-1.41%)

NBL Noble Energy
$8.44 /

+ (+0.00%)

AMTD TD Ameritrade
$40.00 /

-0.79 (-1.94%)

ADRO Aduro Biotech
$0.00 /

+ (+0.00%)

PLTR Palantir
$9.06 /

-0.13 (-1.41%)

NBL Noble Energy
$8.44 /

+ (+0.00%)

AMTD TD Ameritrade
$40.00 /

-0.79 (-1.94%)

PLTR Palantir
$9.06 /

-0.13 (-1.41%)

NBL Noble Energy
$8.44 /

+ (+0.00%)

AMTD TD Ameritrade
$40.00 /

-0.79 (-1.94%)

NBL Noble Energy
$8.44 /

+ (+0.00%)

AMTD TD Ameritrade
$40.00 /

-0.79 (-1.94%)

Hot Stocks
Chinook Therapeutics closes merger with Aduro Biotech » 09:11
10/05/20
10/05
09:11
10/05/20
09:11
KDNY

Chinook Therapeutics

$0.00 /

+ (+0.00%)

, ADRO

Aduro Biotech

$14.01 /

-0.34 (-2.37%)

Chinook Therapeutics…

Chinook Therapeutics (KDNY) announced the closing of its merger with Aduro Biotech (ADRO), Inc. and $115 million private placement financing. The combined company, now known as Chinook Therapeutics, will commence trading October 6, 2020 on the Nasdaq Global Select Market under the trading symbol "KDNY." As previously announced, the $115 million private placement financing includes participation from new investors EcoR1 Capital, OrbiMed Advisors, funds managed by Rock Springs Capital, Fidelity Management and Research Company LLC, Avidity Partners, Surveyor Capital, Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech and other top-tier healthcare investors. As part of the financing, Chinook's existing investors, Versant Ventures, Apple Tree Partners and Samsara BioCapital, purchased $25 million in Chinook common stock on the same terms as the new investors. Effective as of the closing of the merger, Chinook has over $275 million in operating capital to advance its kidney disease programs. Chinook will focus on advancing its product candidates for kidney disease, including: Planned Phase 3 and Phase 2 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases; An ongoing Phase 1b and future clinical trials of BION-1301, an investigational humanized monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, in development for the treatment of IgA nephropathy; A planned Phase 1 trial of CHK-336, an investigational small molecule, in preclinical development for the treatment of an ultra-rare orphan kidney disease; and Advancement of additional research and discovery programs focused on the treatment of rare, severe chronic kidney diseases. In connection with the closing of the merger, Aduro effected a 1:5 reverse split of its common stock. Post-merger and post-reverse split, Chinook has approximately 42 million shares of common stock outstanding. Prior Chinook stockholders collectively own approximately 39.5% of the combined company, prior Aduro stockholders collectively own approximately 39.9% of the combined company and investors in the Chinook private placement financing collectively own approximately 20.6% of the combined company. Effective as of the closing of the merger, the board of directors of Chinook will be comprised of seven directors: Eric Dobmeier, president and chief executive officer of Chinook Therapeutics; Jerel Davis, Ph.D., managing director at Versant Ventures; Srini Akkaraju, M.D., Ph.D., managing general partner at Samsara BioCapital; William M. Greenman, president and chief executive officer of Cerus Corporation; Ross Haghighat, founder, chairman and managing partner of Triton Systems, Inc.; Michelle Griffin, director and audit committee chair for Adaptive Biotechnologies, Acer Therapeutics and HTG Molecular Diagnostics, Inc.; and Dolca Thomas, M.D., chief medical officer of Principia Biopharma, Inc.

ShowHide Related Items >><<
ADRO Aduro Biotech
$14.01 /

-0.34 (-2.37%)

KDNY Chinook Therapeutics
$0.00 /

+ (+0.00%)

ADRO Aduro Biotech
$14.01 /

-0.34 (-2.37%)

06/02/20 H.C. Wainwright
H.C. Wainwright trims Aduro price target to $3.75 after Chinook deal announced
01/10/20 Cowen
Aduro downgraded to Market Perform on limited visibility at Cowen
01/10/20 Cowen
Aduro Biotech downgraded to Market Perform from Outperform at Cowen
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
ADRO Aduro Biotech
$14.01 /

-0.34 (-2.37%)

Conference/Events
Wedbush biotech analyst to hold analyst/industry conference call » 14:07
10/02/20
10/02
14:07
10/02/20
14:07
RTRX

Retrophin

$19.02 /

-0.22 (-1.14%)

Biotechnology Analyst…

Biotechnology Analyst Chico, along with Dr. Howard Trachtman, Professor of Pediatrics Dept at NYU Grossman School of Medicine, discuss Focal Segmental Glomerulosclerosis (FSGS) Therapies in development and the impact to Retrophin (RTRX) on an Analyst/Industry conference call to be held on October 8 at 10 am.

ShowHide Related Items >><<
RTRX Retrophin
$19.02 /

-0.22 (-1.14%)

RTRX Retrophin
$19.02 /

-0.22 (-1.14%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
RTRX Retrophin
$19.02 /

-0.22 (-1.14%)

  • 09
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.